Monthly Update31 Jul 2025, 02:41 pm
IOL Chemicals & Pharmaceuticals Ltd Reports Integrated Annual Report 2024-25 with 31% Growth
AI Summary
IOL Chemicals & Pharmaceuticals Ltd, a leading manufacturer of Active Pharmaceutical Ingredients (APIs), intermediates, and specialty chemicals, has released its Integrated Annual Report 2024-25. The report highlights the company's 31% growth, zero-liquid discharge operations, and a strong global footprint. IOLCP has a backward-integrated supply chain, DSIR-recognised R&D, and regulatory approvals from USFDA, EDQM, and ANVISA. The report also emphasizes the company's strategy of backward integration, operational resilience, and a focus on pharmaceutical and chemical domains.
Key Highlights
- IOLCP reports 31% growth in the financial year 2024-25
- Company operates zero-liquid discharge facilities
- IOLCP is a leading manufacturer of APIs, intermediates, and specialty chemicals
- The company has a strong global footprint and a backward-integrated supply chain
- IOLCP has DSIR-recognised R&D and regulatory approvals from USFDA, EDQM, and ANVISA